# Stephan Rosenkranz

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 107 papers | 6,570 citations | 39 h-index | 80 g-index |
| 124 ext. papers | 8,694 ext. citations | 7.5 avg, IF | 5.67 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 107 | Coagulation-independent effects of thrombin and factor Xa: role of protease-activated receptors in pulmonary hypertension.. *Cardiovascular Research*, **2022**, | 9.9 | 1 |
| 106 | Detection of patients with chronic thromboembolic pulmonary hypertension by volumetric iodine quantification in the lung-a case control study.. *Quantitative Imaging in Medicine and Surgery*, **2022**, 12, 1121-1129 | 3.6 | 2 |
| 105 | Spectral Detector CT-Derived Pulmonary Perfusion Maps and Pulmonary Parenchyma Characteristics for the Semiautomated Classification of Pulmonary Hypertension.. *Frontiers in Cardiovascular Medicine*, **2022**, 9, 835732 | 5.4 | 0 |
| 104 | FGF21 modulates mitochondrial stress response in cardiomyocytes only under mild mitochondrial dysfunction.. *Science Advances*, **2022**, 8, eabn7105 | 14.3 | 3 |
| 103 | Prognostic Power of Pulmonary Arterial Compliance Is Boosted by a Hemodynamic Unloading Test With Glyceryl Trinitrate in Heart Failure Patients With Post-capillary Pulmonary Hypertension.. *Frontiers in Cardiovascular Medicine*, **2022**, 9, 838898 | 5.4 | |
| 102 | European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. *Cardiovascular Research*, **2021**, | 9.9 | 3 |
| 101 | Less loop diuretic use in patients on sacubitril/valsartan undergoing remote pulmonary artery pressure monitoring. *ESC Heart Failure*, **2021**, | 3.7 | 3 |
| 100 | COMPERA 2.0: A refined 4-strata risk assessment model for pulmonary arterial hypertension. *European Respiratory Journal*, **2021**, | 13.6 | 7 |
| 99 | Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. *European Heart Journal*, **2021**, | 9.5 | 7 |
| 98 | The REPAIR Study: Effects of Macitentan on RV Structure and Function in Pulmonary Arterial Hypertension. *JACC: Cardiovascular Imaging*, **2021**, | 8.4 | 4 |
| 97 | The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study. *European Journal of Heart Failure*, **2021**, | 12.3 | 1 |
| 96 | k-t accelerated multi-VENC 4D flow MRI improves vortex assessment in pulmonary hypertension. *European Journal of Radiology*, **2021**, 145, 110035 | 4.7 | 1 |
| 95 | Temporal trends in pulmonary arterial hypertension: Results from the COMPERA registry. *European Respiratory Journal*, **2021**, | 13.6 | 6 |
| 94 | Stamp2 Protects From Maladaptive Structural Remodeling and Systolic Dysfunction in Post-Ischemic Hearts by Attenuating Neutrophil Activation. *Frontiers in Immunology*, **2021**, 12, 701721 | 8.4 | |
| 93 | Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. *Lancet Respiratory Medicine,the*, **2021**, 9, 573-584 | 35.1 | 22 |
| 92 | Quality of Life 3 and 12 Months Following Acute Pulmonary Embolism: Analysis From a Prospective Multicenter Cohort Study. *Chest*, **2021**, 159, 2428-2438 | 5.3 | 5 |
| 91 | Current and future treatments of pulmonary arterial hypertension. *British Journal of Pharmacology*, **2021**, 178, 6-30 | 8.6 | 42 |

| | | | |
|---|---|---|---|
| 90 | Riociguat: Clinical research and evolving role in therapy. *British Journal of Clinical Pharmacology*, **2021**, 87, 2645-2662 | 3.8 | 7 |
| 89 | ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. *European Heart Journal*, **2021**, | 9.5 | 28 |
| 88 | Pulmonale Hypertonie und Rechtsherzinsuffizienz. *Aktuelle Kardiologie*, **2021**, 10, 330-338 | 0.1 | |
| 87 | Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry. *European Respiratory Journal*, **2021**, 58, | 13.6 | 3 |
| 86 | Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long-term study. *Journal of Cachexia, Sarcopenia and Muscle*, **2021**, | 10.3 | 3 |
| 85 | Pulmonale Hypertonie: Differenzialdiagnostik und therapeutische Konsequenzen. *Kardiologie Up2date*, **2021**, 17, 317-333 | 0 | |
| 84 | Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. *Journal of Clinical Medicine*, **2020**, 9, | 5.1 | 8 |
| 83 | Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. *Thrombosis and Haemostasis*, **2020**, 120, 1004-1024 | 7 | 147 |
| 82 | Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE. *International Journal of Cardiology*, **2020**, 317, 188-192 | 3.2 | 3 |
| 81 | Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). *European Journal of Heart Failure*, **2020**, 22, 1891-1901 | 12.3 | 52 |
| 80 | Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure. *Circulation*, **2020**, 141, 678-693 | 16.7 | 39 |
| 79 | Whole-Body Vibration Therapy in Patients with Pulmonary Hypertension and Right Heart Failure: Lessons from a Pilot Study **2020**, 355-362 | | |
| 78 | Pulmonary hypertension associated with left-sided heart failure. *Current Opinion in Cardiology*, **2020**, 35, 610-619 | 2.1 | 4 |
| 77 | Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. *Journal of Heart and Lung Transplantation*, **2020**, 39, 1435-1444 | 5.8 | 24 |
| 76 | Right ventricular dysfunction and long-term risk of death. *Cardiovascular Diagnosis and Therapy*, **2020**, 10, 1646-1658 | 2.6 | 5 |
| 75 | The six-transmembrane protein Stamp2 ameliorates pulmonary vascular remodeling and pulmonary hypertension in mice. *Basic Research in Cardiology*, **2020**, 115, 68 | 11.8 | 4 |
| 74 | COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2020**, 75, 2950-2973 | 15.1 | 1682 |
| 73 | Diagnostic and Therapeutic Gaps in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease. *JACC: Heart Failure*, **2019**, 7, 823-833 | 7.9 | 30 |

| | | | |
|---|---|---|---|
| 72 | Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. *Respiratory Research*, **2019**, 20, 208 | 7.3 | 8 |
| 71 | Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. *Journal of Heart and Lung Transplantation*, **2019**, 38, 1286-1295 | 5.8 | 22 |
| 70 | Diagnosis of pulmonary hypertension using spectral-detector CT. *International Journal of Cardiology*, **2019**, 285, 80-85 | 3.2 | 9 |
| 69 | Differenzialdiagnose ist bei pulmonaler Hypertonie therapieentscheidend. *Pneumo News*, **2019**, 11, 36-38 | | |
| 68 | Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. *International Journal of Cardiology*, **2019**, 283, 152-158 | 3.2 | 18 |
| 67 | Pulmonary hypertension due to left heart´disease. *European Respiratory Journal*, **2019**, 53, | 13.6 | 209 |
| 66 | Risk assessment in pulmonary arterial hypertension. *European Respiratory Journal*, **2018**, 51, | 13.6 | 35 |
| 65 | Pulmonary hypertension associated with left heart disease: Updated Recommendations of the Cologne Consensus Conference 2018. *International Journal of Cardiology*, **2018**, 272S, 53-62 | 3.2 | 32 |
| 64 | Riociguat for the Treatment of Raynaud's Phenomenon: A Single-Dose, Double-Blind, Randomized, Placebo-Controlled Cross-Over Pilot Study (DIGIT). *Clinical Drug Investigation*, **2018**, 38, 1061-1069 | 3.2 | 8 |
| 63 | Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. *European Respiratory Journal*, **2018**, 52, | 13.6 | 25 |
| 62 | Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. *International Journal of Cardiology*, **2018**, 272S, 37-45 | 3.2 | 33 |
| 61 | Right Heart Catheterization for the Diagnosis of Pulmonary Hypertension: Controversies and Practical Issues. *Heart Failure Clinics*, **2018**, 14, 467-477 | 3.3 | 22 |
| 60 | Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis. *Heart*, **2017**, 103, 774-782 | 5.1 | 35 |
| 59 | Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study. *Heart*, **2017**, 103, 592-598 | 5.1 | 20 |
| 58 | Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. *European Journal of Heart Failure*, **2017**, 19, 1651-1660 | 12.3 | 59 |
| 57 | Pulmonale Hypertonie bei Linksherzerkrankungen. *Klinikarzt*, **2017**, 46, 382-388 | 0 | |
| 56 | RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. *European Respiratory Journal*, **2017**, 50, | 13.6 | 74 |
| 55 | Hipertensión pulmonar. Regreso al futuro. *Revista Espanola De Cardiologia*, **2017**, 70, 901-904 | 1.5 | 2 |

| | | | |
|---|---|---|---|
| 54 | ER stress-induced aggresome trafficking of HtrA1 protects against proteotoxicity. *Journal of Molecular Cell Biology*, **2017**, 9, 516-532 | 6.3 | 6 |
| 53 | What can we learn from pulmonary function testing in heart failure?. *European Journal of Heart Failure*, **2017**, 19, 1222-1229 | 12.3 | 27 |
| 52 | Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. *European Respiratory Journal*, **2017**, 50, | 13.6 | 288 |
| 51 | Therapie der pulmonal arteriellen Hypertonie. *Klinikarzt*, **2017**, 46, 374-381 | 0 | |
| 50 | An official European Respiratory Society statement: pulmonary haemodynamics during exercise. *European Respiratory Journal*, **2017**, 50, | 13.6 | 124 |
| 49 | Pulmonary Hypertension. *Deutsches Ärzteblatt International*, **2017**, 114, 73-84 | 2.5 | 57 |
| 48 | Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. *European Heart Journal*, **2017**, 38, 2869-2873 | 9.5 | 64 |
| 47 | Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study. *Journal of Thrombosis and Thrombolysis*, **2016**, 42, 600-9 | 5.1 | 29 |
| 46 | Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum. *Journal of the American College of Cardiology*, **2016**, 68, 368-78 | 15.1 | 148 |
| 45 | Predictors of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement With the SAPIEN 3. *JACC: Cardiovascular Interventions*, **2016**, 9, 2200-2209 | 5 | 119 |
| 44 | Case report: Subjective loss of performance after pulmonary embolism in an athlete- beyond normal values. *BMC Pulmonary Medicine*, **2016**, 16, 21 | 3.5 | 3 |
| 43 | Transfemoral transcatheter aortic valve implantation in a patient with multiple endovascular aortic stents--a case report. *Journal of Cardiothoracic Surgery*, **2016**, 11, 24 | 1.6 | 1 |
| 42 | Gu□ ESC/ERS 2015 sobre diagn□stico y tratamiento de la hipertensi□n pulmonar. *Revista Espanola De Cardiologia*, **2016**, 69, 177.e1-177.e62 | 1.5 | 137 |
| 41 | Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **2016**, 389, 369-79 | 3.4 | 26 |
| 40 | Left ventricular heart failure and pulmonary hypertension. *European Heart Journal*, **2016**, 37, 942-54 | 9.5 | 316 |
| 39 | Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. *Lancet Respiratory Medicine,the*, **2016**, 4, 361-71 | 35.1 | 69 |
| 38 | Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. *Lancet Respiratory Medicine,the*, **2016**, 4, 894-901 | 35.1 | 37 |
| 37 | CT-proET1 predicts pulmonary hemodynamics in Scleroderma-associated pulmonary hypertension. *Clinical Research in Cardiology*, **2015**, 104, 525-9 | 6.1 | 1 |

| | | | |
|---|---|---|---|
| 36 | Genetic Ablation of PDGF-Dependent Signaling Pathways Abolishes Vascular Remodeling and Experimental Pulmonary Hypertension. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 1236-45 | 9.4 | 31 |
| 35 | Class IA Phosphatidylinositol 3-Kinase Isoform p110 Mediates Vascular Remodeling. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 1434-44 | 9.4 | 9 |
| 34 | Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options. *Clinical Research in Cardiology*, **2015**, 104, 197-207 | 6.1 | 35 |
| 33 | Right heart catheterisation: best practice and pitfalls in pulmonary hypertension. *European Respiratory Review*, **2015**, 24, 642-52 | 9.8 | 79 |
| 32 | Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. *Chest*, **2014**, 146, 1274-1285 | 5.3 | 162 |
| 31 | Loss of UCP2 attenuates mitochondrial dysfunction without altering ROS production and uncoupling activity. *PLoS Genetics*, **2014**, 10, e1004385 | 6 | 52 |
| 30 | Response to letters regarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)". *Circulation*, **2014**, 130, e110-2 | 16.7 | 4 |
| 29 | Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). *Circulation*, **2014**, 129, 57-65 | 16.7 | 235 |
| 28 | Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. *International Journal of Cardiology*, **2014**, 175, 233-9 | 3.2 | 52 |
| 27 | Pulmonary arterial hypertension: epidemiology and registries. *Journal of the American College of Cardiology*, **2013**, 62, D51-9 | 15.1 | 338 |
| 26 | Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. *International Journal of Cardiology*, **2013**, 168, 871-80 | 3.2 | 231 |
| 25 | Imatinib mesylate for the treatment of pulmonary arterial hypertension. *Expert Opinion on Investigational Drugs*, **2012**, 21, 119-34 | 5.9 | 50 |
| 24 | Therapeutic potential of sildenafil in patients with heart failure and reactive pulmonary hypertension. *International Journal of Cardiology*, **2012**, 154, 205-6 | 3.2 | 20 |
| 23 | Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. *Archives of Internal Medicine*, **2012**, 172, 1182-4 | | 40 |
| 22 | Cologne Consensus Conference on pulmonary hypertension. *International Journal of Cardiology*, **2011**, 154 Suppl 1, S1-2 | 3.2 | 4 |
| 21 | Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. *International Journal of Cardiology*, **2011**, 154 Suppl 1, S20-33 | 3.2 | 38 |
| 20 | Pulmonary hypertension due to left heart disease: updated Recommendations of the Cologne Consensus Conference 2011. *International Journal of Cardiology*, **2011**, 154 Suppl 1, S34-44 | 3.2 | 21 |
| 19 | Transforming growth factor oppositely regulates the hypertrophic and contractile response to adrenergic stimulation in the heart. *PLoS ONE*, **2011**, 6, e26628 | 3.7 | 40 |

| | | | |
|---|---|---|---|
| 18 | The Arg389Gly β1-adrenoceptor gene polymorphism influences the acute effects of β-adrenoceptor blockade on contractility in the human heart. *Clinical Research in Cardiology*, **2011**, 100, 641-7 | 6.1 | 9 |
| 17 | Hypoxia enhances platelet-derived growth factor signaling in the pulmonary vasculature by down-regulation of protein tyrosine phosphatases. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 1092-102 | 10.2 | 64 |
| 16 | Profilin-1 is expressed in human atherosclerotic plaques and induces atherogenic effects on vascular smooth muscle cells. *PLoS ONE*, **2010**, 5, e13608 | 3.7 | 40 |
| 15 | PDGF-BB protects cardiomyocytes from apoptosis and improves contractile function of engineered heart tissue. *Journal of Molecular and Cellular Cardiology*, **2010**, 48, 1316-23 | 5.8 | 36 |
| 14 | Beta1-adrenoceptor polymorphism predicts flecainide action in patients with atrial fibrillation. *PLoS ONE*, **2010**, 5, e11421 | 3.7 | 14 |
| 13 | Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. *Clinical Research in Cardiology*, **2009**, 98, 265-7 | 6.1 | 40 |
| 12 | Influence of cell treatment with PDGF-BB and reperfusion on cardiac persistence of mononuclear and mesenchymal bone marrow cells after transplantation into acute myocardial infarction in rats. *Cell Transplantation*, **2009**, 18, 847-53 | 4 | 27 |
| 11 | Pulmonary hypertension: current diagnosis and treatment. *Clinical Research in Cardiology*, **2007**, 96, 527-41 | 6.1 | 53 |
| 10 | PI3-kinase/Akt-dependent antiapoptotic signaling by the PDGF alpha receptor is negatively regulated by Src family kinases. *FEBS Letters*, **2006**, 580, 6769-76 | 3.8 | 20 |
| 9 | Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. *Archives of Internal Medicine*, **2006**, 166, 231-3 | | 67 |
| 8 | Phosphodiesterase type 5 inhibitor sildenafil citrate does not potentiate the vasodilative properties of nebivolol in rat aorta. *Life Sciences*, **2006**, 78, 1103-7 | 6.8 | 6 |
| 7 | Systematic evaluation of anti-apoptotic growth factor signaling in vascular smooth muscle cells. Only phosphatidylinositol 3Rkinase is important. *Journal of Biological Chemistry*, **2005**, 280, 14168-76 | 5.4 | 43 |
| 6 | The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines. *Pharmacogenetics and Genomics*, **2004**, 14, 711-6 | | 52 |
| 5 | Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon. *Annals of Internal Medicine*, **2003**, 139, 871-3 | 8 | 56 |
| 4 | Src family kinases negatively regulate platelet-derived growth factor alpha receptor-dependent signaling and disease progression. *Journal of Biological Chemistry*, **2000**, 275, 9620-7 | 5.4 | 46 |
| 3 | Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AA-dependent chemotaxis and DNA synthesis. *Journal of Biological Chemistry*, **1999**, 274, 28335-43 | 5.4 | 64 |
| 2 | Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. *Growth Factors*, **1999**, 16, 201-16 | 1.6 | 173 |
| 1 | A role for Src in signal relay by the platelet-derived growth factor alpha receptor. *Journal of Biological Chemistry*, **1998**, 273, 5908-15 | 5.4 | 71 |